10-QThe Record
TEVA PHARMACEUTICAL INDUSTRIES LTD files 10-Q
Filed Apr 29, 2026 · 2mo ago · Accession 0001193125-26-191513
Plain English
Teva Pharmaceutical Industries Limited reported a net income of $369 million for the first quarter of 2026, an increase from $214 million in the prior year's quarter, driven by higher operating income. The company also announced an agreement to acquire Emalex Biosciences for $700 million, expected to close in the third quarter of 2026.
Filing details
- Ticker
- TEVA
- CIK
- 818686
- Form type
- 10-Q
- Filing date
- Apr 29, 2026
- Report date
- Mar 31, 2026
- Document
- d115083d10q.htm
- Size
- 11.2 MB